Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Corticosteroids Combined with Cyclosporine a Is Superior to Corticosteroids As First-Line Treatment for Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation

Weiran Lv, Hong Qu, Meiqing Wu, Zhiping Fan, MD, Fen Huang, Na Xu, PhD, Li Xuan, Ren Lin, Ke Zhao, Jing Sun, Yongrong Lai, MD, Yajing Xu, MD PhD, Qifa Liu, MD

Blood (2018) 132 (Supplement 1): 5736.

https://doi.org/10.1182/blood-2018-99-114043

Published: 2018

Journal Articles

Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension

Dudley J Pennell, MD, John B Porter, MD, Antonio Piga, MD, Yongrong Lai, MD, Amal El-Beshlawy, MD, Khawla Belhoul, MD, Mohsen Elalfy, MD, Akif Yesilipek, MD, Yurdanur Kilinç, MD, Antje Wegener, MD, Dany Habr, MD, Junwu Shen, PhD, Yesim Aydinok, MD

Blood (2013) 122 (21): 1018.

https://doi.org/10.1182/blood.V122.21.1018.1018

Published: 2013

Journal Articles

Graft-Versus-Host Disease Following Myeloablative Busulfan Plus Fludarabine and Busulfan Plus Cyclophosphamide For Allogeneic Hematopoietic Stem Cell Transplantation In Acute Myeloid Leukemia In First Complete Remission

Qifa Liu, MD, Hui Liu, Daihong Liu, Yongrong Lai, MD, Jing Sun, MD, Chaoyang Song, Yu Zhang, Yang Xiao, MD, Fen Huang, MD, Hongsheng Zhou, Zhiping Fan, Xutao Guo, M.D., Danian Nie, MD, Guopan Yu, MD&M Sci, Xiaojun Huang

Blood (2013) 122 (21): 3290.

https://doi.org/10.1182/blood.V122.21.3290.3290

Published: 2013

Journal Articles

A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA).

Dudley J Pennell, MD, John B Porter, MD, Antonio Piga, MD, Yongrong Lai, MD, Amal El-Beshlawy, MD, Khawla Beloul, MD, Mohsen Elalfy, MD, Akif Yesilipek, MD, Yurdanur Kilinç, MD, Tomasz Lawniczek, MD, Dany Habr, MD, Marianne Weisskopf, PhD, Yiyun Zhang, PhD, Yesim Aydinok, MD

Blood (2012) 120 (21): 2124.

https://doi.org/10.1182/blood.V120.21.2124.2124

Published: 2012

Journal Articles

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

John B Porter, MD, Mohsen Elalfy, MD, Vip Viprakasit, MD, DPhil, Stephane Giraudier, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 2126.

https://doi.org/10.1182/blood.V120.21.2126.2126

Published: 2012

Journal Articles

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Amal El-Beshlawy, MD, Mohsen Elalfy, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Kai-Hsin Lin, MD, Yesim Aydinok, MD, Renzo Galanello, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 1028.

https://doi.org/10.1182/blood.V120.21.1028.1028

Published: 2012

NARROW

Corticosteroids Combined with Cyclosporine a Is Superior to Corticosteroids As First-Line Treatment for Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation

Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension

Graft-Versus-Host Disease Following Myeloablative Busulfan Plus Fludarabine and Busulfan Plus Cyclophosphamide For Allogeneic Hematopoietic Stem Cell Transplantation In Acute Myeloid Leukemia In First Complete Remission

A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA).

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Email alerts

ASH Publications

American Society of Hematology

Corticosteroids Combined with Cyclosporine a Is Superior to Corticosteroids As First-Line Treatment for Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation

Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension

Graft-Versus-Host Disease Following Myeloablative Busulfan Plus Fludarabine and Busulfan Plus Cyclophosphamide For Allogeneic Hematopoietic Stem Cell Transplantation In Acute Myeloid Leukemia In First Complete Remission

A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA).

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only